Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Artículo
|
Targeting immunoliposomes to EGFR-positive glioblastomaKasenda, B. ; König, D. ; Manni, M. ; Ritschard, R. ; Duthaler, U. ; Bartoszek, E. ; Bärenwaldt, A. ; Deuster, S. ; Hutter, G. ; Cordier, D. ; Mariani, L. ; Hench, J. ; Frank, S. ; Krähenbühl, S. ; Zippelius, A. ; Rochlitz, C. ; Mamot, C. ; Wicki, A. ; Läubli, H.ESMO open, 2022-02, Vol.7 (1), p.100365-100365, Article 100365 [Revista revisada por pares]England: Elsevier LtdTexto completo disponible |
|
2 |
Material Type: Artículo
|
Amplification of SKI Is a Prognostic Marker in Early Colorectal CancerBuess, Martin ; Terracciano, Luigi ; Reuter, Jürgen ; Ballabeni, Pierluigi ; Boulay, Jean-Louis ; Laffer, Urban ; Metzger, Urs ; Herrmann, Richard ; Rochlitz, Christoph F.Neoplasia (New York, N.Y.), 2004-05, Vol.6 (3), p.207-212 [Revista revisada por pares]United States: Elsevier IncTexto completo disponible |
|
3 |
Material Type: Artículo
|
Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized phase III trial SAKK 22/99Pagani, O. ; Klingbiel, D. ; Ruhstaller, T. ; Nolè, F. ; Eppenberger, S. ; Oehlschlegel, C. ; Bernhard, J. ; Brauchli, P. ; Hess, D. ; Mamot, C. ; Munzone, E. ; Pestalozzi, B. ; Rabaglio, M. ; Aebi, S. ; Ribi, K. ; Rochlitz, C. ; Rothgiesser, K. ; Thürlimann, B. ; von Moos, R. ; Zaman, K. ; Goldhirsch, A.Annals of oncology, 2017-02, Vol.28 (2), p.305-312 [Revista revisada por pares]England: Elsevier LtdTexto completo disponible |
|
4 |
Material Type: Artículo
|
Communication skills training in oncology: a position paper based on a consensus meeting among European experts in 2009Stiefel, F. ; Barth, J. ; Bensing, J. ; Fallowfield, L. ; Jost, L. ; Razavi, D. ; Kiss, A.Annals of oncology, 2010-02, Vol.21 (2), p.204-207 [Revista revisada por pares]Oxford: Elsevier LtdTexto completo disponible |
|
5 |
Material Type: Artículo
|
268P Anti-EGFR-immunoliposomes loaded with doxorubicin in patients with advanced triple-negative, EGFR positive breast cancer: A multicenter single arm phase II trial [SAKK 24/14]Wicki, A. ; Mamot, C. ; Hasler-Strub, U. ; Riniker, S. ; Li, Q. ; Holer, L. ; Baertschi, D. ; Zaman, K. ; von Moos, R. ; Dedes, K.J. ; Novak, U. ; Bodmer, A. ; Ritschard, R. ; Obermann, E. ; Ackermann, C.J. ; Membrez-Antonioli, V. ; Zuerrer, U. ; Caspar, C.B. ; Rochlitz, C. ; Winterhalder, R.C.Annals of oncology, 2021-09, Vol.32, p.S479-S479 [Revista revisada por pares]Elsevier LtdTexto completo disponible |
|
6 |
Material Type: Artículo
|
345P Optimal dose of eribulin as first line treatment in elderly patients ≥ 70 years with advanced breast cancer: A multicenter phase II trial [SAKK 25/14]Hasler-Strub, U. ; Mueller, A. ; Li, Q. ; Thuerlimann, B.J.K. ; Gerber, S. ; von Moos, R. ; Fehr, M. ; Rochlitz, C. ; Zaman, K. ; Aebi, S. ; Hochstrasser, A.M. ; Gick, U. ; Ribi, K. ; Baertschi, D. ; Greuter, S. ; Schreiber, A. ; Caspar, C.B. ; Trojan, A. ; Condorelli, R. ; Ruhstaller, T.Annals of oncology, 2020-09, Vol.31, p.S385-S385 [Revista revisada por pares]Elsevier LtdTexto completo disponible |
|
7 |
Material Type: Artículo
|
1943 Adjuvant treatment recommendations for ER+ early breast cancer patients by Swiss tumor boards (SAKK 26/10)Pestalozzi, B.C ; Tausch, C ; Dedes, K.J ; Rochlitz, C ; Zimmermann, S ; Von Moos, R ; Winterhalder, R.C ; Ruhstaller, T ; Mueller, A ; Buser, K.S ; Borner, M.M ; Novak, U ; Uhlmann Nussbaum, C ; Seifert, B ; Bigler, M ; Bize, V ; Berardi Vilei, S ; Rageth, C ; Aebi, S.PEuropean journal of cancer (1990), 2015-09, Vol.51, p.S313-S313 [Revista revisada por pares]Elsevier LtdTexto completo disponible |
|
8 |
Material Type: Artículo
|
Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06)Rochlitz, C. ; Ruhstaller, T. ; Lerch, S. ; Spirig, C. ; Huober, J. ; Suter, T. ; Bühlmann, M. ; Fehr, M. ; Schönenberger, A. ; von Moos, R. ; Winterhalder, R. ; Rauch, D. ; Müller, A. ; Mannhart-Harms, M. ; Herrmann, R. ; Cliffe, B. ; Mayer, M. ; Zaman, K.Annals of oncology, 2011-01, Vol.22 (1), p.80-85 [Revista revisada por pares]Oxford: Elsevier LtdTexto completo disponible |
|
9 |
Material Type: Artículo
|
Long-term responders to trastuzumab monotherapy in the first-line metastatic setting: characteristics and survival data (SAKK 22/99 Trial)Schmid, S. ; Klingbiel, D. ; Goldhirsch, A. ; Oehlschlegel, C. ; Munzone, E. ; Nolè, F. ; Pestalozzi, B. ; Aebi, S. ; Rochlitz, C. ; von Moos, R. ; Zaman, K. ; Mamot, C. ; Weder, P. ; Thuerlimann, B. ; Pagani, O. ; Ruhstaller, T.Annals of oncology, 2017-09, Vol.28, p.v99-v99 [Revista revisada por pares]Elsevier LtdTexto completo disponible |
|
10 |
Material Type: Artículo
|
Optimization of bio-ethanol autothermal reforming and carbon monoxide removal processesMarkova, D. ; Bazbauers, G. ; Valters, K. ; Alhucema Arias, R. ; Weuffen, C. ; Rochlitz, L.Journal of power sources, 2009-08, Vol.193 (1), p.9-16 [Revista revisada por pares]Amsterdam: Elsevier B.VTexto completo disponible |